Small Molecules in Oncology pp 57-65 | Cite as
Crizotinib
Abstract
Crizotinib is an ATP-competitive small-molecule inhibitor of the receptor tyrosine kinases (RTK) C-Met, ALK and ROS1. There is a robust effectiveness in non-small-cell lung cancer (NSCLC) harbouring EML4-ALK-rearrangements resulting in constitutional activation of the ALK-RTK. The drug is approved for this entity, which represents no more than 3–5% of all NSCLC. However, in this population, impressive response rates are generated. The same is true for ROS-1 rearrangements; however, these only occur in approximately 1% of all NSCLC. In small series, efficacy is also reported in patients, whose tumours harbour a MET Exon 4 skipping mutation (approx. 3% of all NSCLC). Toxicities include visual impairment, nausea, peripheral edema, QT-prolongation and liver-enzyme elevation. Also, the occurrence of renal cysts is reported. The detection of ALK-protein by immunohistochemistry is a predictor of efficacy for crizotinib. In cases of doubt, fluorescence in situ hybridisation (FISH) detecting the ALK-rearrangement has to be performed on tumour tissue. FISH is also the method of choice to detect ROS1-rearrangement, whereas MET-mutations are detected by sequencing methods. The high efficacy of crizotinib in ALK- and ROS-rearranged as well as MET mutated lung cancer as new molecular targets beside the epidermal growth factor receptor (EGFR) underscores the importance of molecular typing in NSCLC.
Keywords
Crizotinib ALK-Rearrangement C-MET ROS-1References
- Awad MM, Leonardi GC, Kravets S et al (2017) Impact of MET inhibitors on survival among patients (pts) with MET exon 14 mutant (METdel14) non-small cell lung cancer (NSCLC). J Clin Oncol: Off J Am Soc Clin Oncol 35Google Scholar
- Camidge DR, Bang YJ, Kwak EL et al (2012) Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 13:1011–1019CrossRefPubMedPubMedCentralGoogle Scholar
- Choi YL, Soda M, Yamashita Y et al (2010) EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 363:1734–1739CrossRefPubMedGoogle Scholar
- Christensen JG, Zou HY, Arango ME et al (2007) Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol Cancer Ther 6:3314–3322CrossRefPubMedGoogle Scholar
- Cilloni D, Carturan S, Bracco E et al (2013) Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia. Leuk Res 37:520–530CrossRefPubMedGoogle Scholar
- Costa DB, Kobayashi S, Pandya SS et al (2011) CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol: Off J Am Soc Clin Oncol 29:e443–e445CrossRefGoogle Scholar
- Cui JJ, Tran-Dube M, Shen H et al (2011) Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J Med Chem 54:6342–6363CrossRefPubMedGoogle Scholar
- Curran MP (2012) Crizotinib: in locally advanced or metastatic non-small cell lung cancer. Drugs 72:99–107CrossRefPubMedGoogle Scholar
- Fleuren ED, Roeffen MH, Leenders WP et al (2013) Expression and clinical relevance of MET and ALK in Ewing sarcomas. Int J Cancer 133:427–436CrossRefPubMedGoogle Scholar
- Frampton GM, Ali SM, Rosenzweig M et al (2015) Activation of MET via diverse exon 14 splicing alterations occurs in multiple tumor types and confers clinical sensitivity to MET inhibitors. Cancer Discov 5:850–859CrossRefPubMedGoogle Scholar
- Gainor JF, Dardaei L, Yoda S et al (2016) Molecular mechanisms of resistance to first- and second-generation ALK inhibitors in ALK-rearranged lung cancer. Cancer Discov 6:1118–1133CrossRefPubMedPubMedCentralGoogle Scholar
- Inc. P. Xalkori (Crizotinib) Prescribing Information. 2012Google Scholar
- Kwak EL, Bang YJ, Camidge DR et al (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693–1703CrossRefPubMedPubMedCentralGoogle Scholar
- Lee J, Lee SE, Kang SY et al (2013) Identification of ROS1 rearrangement in gastric adenocarcinoma. Cancer 119:1627–1635CrossRefPubMedGoogle Scholar
- Lee J, Ou SH, Lee JM et al (2015) Gastrointestinal malignancies harbor actionable MET exon 14 deletions. Oncotarget 6:28211–28222PubMedPubMedCentralGoogle Scholar
- Matthay KK, George RE, Yu AL (2012) Promising therapeutic targets in neuroblastoma. Clin Cancer Res 18:2740–2753CrossRefPubMedPubMedCentralGoogle Scholar
- Mok T, Kim D, Wu Y et al (2017) Overall survival (OS) for first-line crizotinib versus chemotherapy in ALK+ lung cancer: updated results from PROFILE 1014. Ann Oncol 28:v605–v649Google Scholar
- Mosse YP, Voss SD, Lim MS et al (2017) Targeting ALK with crizotinib in pediatric anaplastic large cell lymphoma and inflammatory myofibroblastic tumor: a children’s oncology group study. J Clin Oncol: Off J Am Soc Clin Oncol 35:3215–3221CrossRefGoogle Scholar
- Okamoto W, Okamoto I, Arao T et al (2012) Antitumor action of the MET tyrosine kinase inhibitor crizotinib (PF-02341066) in gastric cancer positive for MET amplification. Mol Cancer Ther 11:1557–1564CrossRefPubMedGoogle Scholar
- Ordemann R, Stohlmacher J, Beuthien-Baumann B et al (2013) Use of targeted therapy for refractory ALK-positive anaplastic large cell lymphoma as a bridging strategy prior to allogeneic transplantation. Ann Hematol 92:125–127CrossRefPubMedGoogle Scholar
- Peters S, Camidge DR, Shaw AT et al (2017) Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. N Engl J Med 377:829–838CrossRefPubMedGoogle Scholar
- Rodig SJ, Shapiro GI (2010) Crizotinib, a small-molecule dual inhibitor of the c-Met and ALK receptor tyrosine kinases. Curr Opin Invest Drugs 11:1477–1490Google Scholar
- Sasaki T, Okuda K, Zheng W et al (2010) The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res 70:10038–10043CrossRefPubMedPubMedCentralGoogle Scholar
- Shaw AT, Yeap BY, Solomon BJ et al (2011) Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 12:1004–1012CrossRefPubMedPubMedCentralGoogle Scholar
- Shaw AT, Kim DW, Nakagawa K et al (2013) Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J MedGoogle Scholar
- Shaw AT, Ou SH, Bang YJ et al (2014) Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371:1963–1971CrossRefPubMedPubMedCentralGoogle Scholar
- Solomon BJ, Mok T, Kim DW et al (2014) First-line crizotinib versus chemotherapy in ALK-positive lung cancer. N Engl J Med 371:2167–2177CrossRefPubMedGoogle Scholar
- Tang SC, Nguyen LN, Sparidans RW, Wagenaar E, Beijnen JH, Schinkel AH (2014) Increased oral availability and brain accumulation of the ALK inhibitor crizotinib by coadministration of the P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) inhibitor elacridar. Int J Cancer 134:1484–1494CrossRefPubMedGoogle Scholar
- Tothova Z, Wagner AJ (2012) Anaplastic lymphoma kinase-directed therapy in inflammatory myofibroblastic tumors. Curr Opin Oncol 24:409–413CrossRefPubMedGoogle Scholar
- von Laffert M, Schirmacher P, Warth A et al (2016) Statement of the German Society for Pathology and the working group thoracic oncology of the working group oncology/German Cancer Society on ALK testing in NSCLC: immunohistochemistry and/or FISH? Pathologe 37:187–192CrossRefGoogle Scholar
- Yasuda H, de Figueiredo-Pontes LL, Kobayashi S, Costa DB (2012) Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J Thorac Oncol 7:1086–1090CrossRefPubMedPubMedCentralGoogle Scholar
- Zou HY, Li Q, Lee JH et al (2007) An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res 67:4408–4417CrossRefPubMedGoogle Scholar